

Clinical Policy: Celecoxib (Celebrex)
Reference Number: HIM.PA.54
Effective Date: 12/14
Last Review Date: 08/17
Line of Business: Health Insurance Marketplace

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Celecoxib (Celebrex[®]) is a nonsteroidal anti-inflammatory drug (NSAID).

FDA approved indication

Celebrex is indicated:

- For the treatment of osteoarthritis (OA)
- For the treatment of rheumatoid arthritis (RA)
- For the treatment of juvenile rheumatoid arthritis (JRA) in patients 2 years and older
- For the treatment of ankylosing spondylitis (AS)
- For the treatment of acute pain (AP)
- For the treatment of primary dysmenorrhea (PD)

Policy/Criteria

Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria

I. Initial Approval Criteria

A. Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Pain, Primary Dysmenorrhea (must meet all):

1. Diagnosis of OA, RA, JRA, AS, AP, or PD;
2. Failure of meloxicam and two other formulary NSAIDs, each trialed at maximum prescription strength for four weeks unless contraindicated or clinically significant adverse effects are experienced;
3. Dose does not exceed:
 - a. OA: 200 mg/day;
 - b. RA: 400 mg/day;
 - c. JRA: 100 mg/day if weight ≥ 10 kg to ≤ 25 kg, 200 mg/day if weight ≥ 25 kg;
 - d. AS: 400 mg/day;
 - e. AP and PD: 400 mg/day.

Approval duration: 12 months

B. Other diagnoses/indications

1. Refer to HIM.PHAR.21 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Pain, Primary Dysmenorrhea (must meet all):

CLINICAL POLICY

Celecoxib

1. Currently receiving medication via health plan benefit or member has previously met initial approval criteria;
2. Documentation of positive response to therapy;
3. Dose does not exceed:
 - a. OA: 200 mg/day;
 - b. RA: 400 mg/day;
 - c. JRA: 100 mg/day if weight ≥ 10 kg to ≤ 25 kg, 200 mg/day if weight ≥ 25 kg;
 - d. AS: 400 mg/day;
 - e. AP and PD: 400 mg/day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 12 months (whichever is less); or

2. Refer to HIM.PA.21 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized)

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – HIM.PA.21 or evidence of coverage documents

IV. Appendices/General Information

Appendix A: Abbreviation Key

AS: ankylosing spondylitis

AP: acute pain

COX2: cyclooxygenase-2

FDA: Food and Drug Administration

JRA: juvenile rheumatoid arthritis

NSAID: nonsteroidal anti-inflammatory drug

OA: osteoarthritis

PD: primary dysmenorrhea

RA: rheumatoid arthritis

V. References

1. Celebrex Prescribing Information. New York, NY: Pfizer; May 2016. Available at: http://www.pfizer.com/files/products/uspi_celebrex.pdf. Accessed January 17, 2017.
2. Clinical Pharmacology Web site. Available at: <http://www.clinicalpharmacology-ip.com/default.aspx>. Accessed January 17, 2017.
3. Facts and Comparisons eAnswers. Accessed May 2016
4. Celebrex. American Hospital Formulary Service Drug Information. Available at: <https://www.medicinescomplete.com/mc/ahfs/current/>. Accessed January 17, 2017.

CLINICAL POLICY

Celecoxib

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Changed guideline to new format. Streamlined approval criteria. Removed previous sections A, C and D (A.Documentation that patient is not an appropriate candidate for NSAID therapy (See “Special Instructions” for details), C.No reported allergy to sulfonamides, or ASA or other NSAIDs (e.g., asthma, urticaria or other allergic reaction), D. Patient does not have severe renal insufficiency - an eGFR (estimated glomerular filtration rate) below 30 OR severe hepatic impairment (Child-Pugh Class C))	08/16	08/16
Converted to new template Added max dose information Added abbreviations in appendix A Updated references	04/17	08/17

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

CLINICAL POLICY

Celecoxib

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.